AbbVie

AbbVie’s mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas –immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on X, Facebook, Instagram, YouTube, LinkedIn and Tik Tok.

1 North Waukegan Road
North Chicago, IL 60064

Visit website

Stock Symbol: ABBV
Stock Exchange: NYSE

Together, we break through.

Our principles are at the Heart of our Company. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world.

How we work with each other and achieve results matters. That’s why we’ve been honored to receive some of the most prestigious ratings and recognitions in the industry, including being named on more than 40 Great Place to Work and Top Employer lists and FORTUNE “100 Best Companies to Work For.”

Click here to learn more about our principles.

NEWS

Business

Sosei Heptares and AbbVie Partner on Inflammatory and Autoimmune Diseases

The companies will work to discover, develop and commercialize novel therapies that modulate G protein-coupled receptor (GPCR) targets that AbbVie selects.

June 25, 2020

3 min read

Mark Terry

BioMidwest

AbbVie and Alpine Immune Ink $865 Million Deal to License Drug for Lupus and Other Inflammatory Diseases

Under the terms of the deal, AbbVie is paying Alpine an upfront payment of $60 million for rights to ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.

June 18, 2020

3 min read

Mark Terry

BioMidwest

AbbVie’s Venclexta and Chemo Combination Decreases Death by 34% in AML

AbbVie reported positive results from the VIALE-A clinical trial of Venclexta plus azacytidine in previously untreated acute myeloid leukemia (AML) patients who were ineligible for intensive chemotherapy.

June 15, 2020

2 min read

Mark Terry

Business

AbbVie Plunks Down $750 Million Upfront for Cancer Therapy Deal with Genmab

The collaboration will focus on the development of three of Genmab’s bispecific antibodies and will also involve a discovery research collaboration for future antibody therapeutics for cancer.

June 10, 2020

3 min read

Alex Keown

BioForest

Clinical Catch-Up: May 31-June 5

As summer begins, we’re seeing a shift away from COVID-19-related news and a stronger output of other clinical trial news. Here’s a look.

June 5, 2020

10 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: June 5

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 5, 2020.

June 5, 2020

3 min read

BioSpace Editorial Staff

Oriahnn is the new non-surgical treatment for heav

FDA

FDA Approves New Treatment Oriahnn for Heavy Menstrual Bleeding Associated with Uterine Fibroids

AbbVie won first-of-its-kind approval for a non-surgical treatment, Oriahnn, aimed at treating heavy menstrual bleeding due to uterine fibroids, a common non-cancerous tumor, in pre-menopausal women.

June 1, 2020

2 min read

Alex Keown

Drug Development

Following Phase II Failure, Ironwood and AbbVie Halt Development of Delayed-Release Linzess

Ironwood and AbbVie said a Phase II trial assessing the drug candidate MD-7246, a delayed-release formulation of Linzess, did not meet its primary or key secondary endpoints.

May 29, 2020

2 min read

Alex Keown

Drug Development

Biotech Bay Companies Fighting Against COVID-19

Biotech Bay, the bustling biotech industry around San Francisco in California, is home to many biopharma companies developing diagnostics, therapies, and vaccines to fight against coronavirus disease 2019 (COVID-19) and the virus that causes it, called SARS-CoV-2.

May 22, 2020

11 min read

Chelsea Weidman Burke, M.S.

JOBS